51 results
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
assessment, fine or penalty levied against any of them, except (i) as are being contested in good faith and as to which adequate reserves have been
S-3
EX-5.1
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
consideration, analysis or assessment of whether the National Security & Investment Act 2021 (“NS&IA”) may or will apply to any of the transactions
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
and is suitable for use as a key Clinical Outcomes Assessment endpoint.
The global Phase 3 study, which is supported by positive data from the ASTRAEUS
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
the results of such assessment to the board; and
developing and recommending to the Board rules governing the board, reviewing and reassessing the adequacy
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
with or statement from the FDA on a Special Protocol Assessment or equivalent, or (ii) other guidance or minutes issued by the FDA, or (iii
10-K
k2ltz72ipy 2p
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
26fisf68 k51p
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
S-8
EX-4.3
k927274h0k1tyo
23 Jan 24
Registration of securities for employees
4:16pm
8-K
EX-99.1
kzy5sgyv10j8v
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-99.1
6klnxs wfu2
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.2
sm5gf627 4mhn0
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
11lr9
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
be4699wq
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
sfcgo978n8 zv7
9 May 22
Current report (foreign)
8:06am
6-K
EX-99.1
jp74c
9 May 22
Current report (foreign)
8:06am
6-K
EX-99.1
6m2wy
22 Dec 21
Alvelestat reported safe and well-tolerated in patients with COVID-19
7:45am
F-3
EX-1.2
rtv50rlw3y01thjr85
5 Aug 21
Shelf registration (foreign)
4:33pm
6-K
EX-99.1
fvns1
30 Apr 21
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
4:05pm